Tag Archive for: AKI

Mission Therapeutics raises £25.2 million to progress clinical candidates in the area of mitophagy

• Developing novel therapeutics which enhance the removal of dysfunctional mitochondria, promoting cell health and function • MTX325 is a potentially disease-modifying treatment for Parkinson’s Disease with clinical trial due to start imminently • Backed by blue chip international investors Cambridge, UK – March 14, 2024 – Mission Therapeutics (“Mission” or the “Company”), a clinical-stage biotech […]

Mission Therapeutics announces US FDA approval to initiate Phase II clinical trial of its lead asset MTX652 in Acute Kidney Injury

Mission gains clearance from US FDA for Phase II trial of MTX562 after it receives official approval of its Investigational New Drug (IND) application Phase II trial expected to begin Q1 2024 in up to 160 patients with acute kidney injury (AKI) following cardiac surgery Cambridge, UK – December 14, 2023 – Mission Therapeutics (“Mission” […]

Mission Therapeutics to Present Abstract at American Society of Nephrology (ASN) Kidney Week 2023

CAMBRIDGE, UK, 2 November 2023 – Mission Therapeutics (“Mission”), a clinical-stage biotech company developing first-in-class therapeutics targeting mitophagy, today announces that it will present an oral abstract on its experimental drug candidate MTX652 at the American Society of Nephrology’s Kidney Week in Philadelphia, from 2-5 November 2023. Mission Therapeutics is a world leader in discovering and developing novel […]